Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACU-0943
- Development stage
- Preclinical
- Lead developer
- Aculeus Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
ACU-0943 is a proprietary small molecule drug developed by Aculeus Therapeutics that acts as an agonist of the STING (Stimulator of Interferon Genes) pathway. By activating STING, ACU-0943 boosts immune responses against cancer cells, particularly in acute myeloid leukemia (AML). Preclinical studies have shown that combining ACU-0943 with venetoclax leads to highly effective killing of AML cancer cells, including those with mutated p53 protein—a form typically resistant to standard therapies. The drug is being advanced for intravenous administration and is expected to enter clinical development for AML[1][2][4][5][6][7].
02
Targets
STING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on ACU-0943.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACU-0943.